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ABSTRACT
Introduction: The efficacy and safety of
canagliflozin, a sodium glucose co-transporter
2 (SGLT2) inhibitor, was evaluated in patients
with type 2 diabetes mellitus (T2DM)
inadequately controlled on sulfonylurea
monotherapy.
Methods: The CANagliflozin cardioVascular
Assessment Study (CANVAS) is a double-blind,
placebo-controlled cardiovascular outcomes
study that randomized participants to placebo
or canagliflozin 100 or 300 mg once daily in
addition to routine therapy. Participants in the
CANVAS trial are men and women aged
C30 years with T2DM and a history or high
risk of cardiovascular disease, and inadequate
glycemic control (glycated hemoglobin [HbA1c]
C7.0% and B10.5%) on current
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antihyperglycemic therapies. The primary
objective of this prespecified substudy was to
assess change from baseline to 18 weeks in
HbA1c among patients on sulfonylurea
monotherapy.
Results: Of the 4330 patients enrolled in
CANVAS, 127 met the entry criteria for the
sulfonylurea monotherapy substudy (placebo,
n = 45; canagliflozin 100 mg, n = 42;
canagliflozin 300 mg, n = 40). At 18 weeks,
placebo-subtracted changes (95% confidence
interval) in HbA1c were -0.74% (-1.15,
-0.33; P\0.001) and -0.83% (-1.24, -0.42;
P\0.001) with canagliflozin 100 and 300 mg,
respectively. Relative to placebo, canagliflozin
100 and 300 mg also decreased fasting plasma
glucose (FPG; -2.1 mmol/L [-3.0, -1.2] and
-2.7 mmol/L [-3.6, -1.7], respectively). Body
weight was lower with canagliflozin 300 mg
(–1.8% [-3.2, -0.4]; P = 0.014) but unchanged
with canagliflozin 100 mg (-0.4% [-1.8, 1.0];
P = 0.557). Canagliflozin 300 mg increased
hypoglycemia episodes compared to
canagliflozin 100 mg and placebo (15%, 0%,
and 4.4%, respectively). Adverse events (AEs) of
male and female genital mycotic infections,
pollakiuria, and thirst were more common with
canagliflozin.
Conclusions: Canagliflozin added to ongoing
sulfonylurea monotherapy produced
improvements in HbA1c, FPG, and body weight,
with an increased incidence of AEs consistent with
the mechanism of action of SGLT2 inhibition.
Funding: Janssen Research & Development,
LLC.
Clinical trial registration: ClinicalTrials.gov
NCT01032629.
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INTRODUCTION
Type 2 diabetes mellitus (T2DM) is a progressive
disease that often requires combination therapy
with antihyperglycemic agents (AHAs) to
achieve and maintain glycemic control [1].
Metformin is the most widely recommended
initial monotherapy approach, but some
patients are started first with sulfonylureas
either for intolerance to metformin or because
of physician and/or patient preferences despite
the known adverse effects, such as
hypoglycemia and weight gain [1]. As the
sulfonylurea glucose-lowering effects are not
sustained, many patients fail to achieve
individualized glycemic targets and will need
additional therapy [2, 3]. Accordingly, the
availability of new agents that can lower blood
glucose levels with good safety and tolerability,
without increasing hypoglycemia risk and
ideally neutralizing the sulfonylurea-induced
weight gain, may have significant potential in
the future management of the condition.
Canagliflozin is a sodium glucose co-
transporter 2 (SGLT2) inhibitor approved in
the United States and elsewhere as an adjunct to
diet and exercise to improve glycemic control in
adults with T2DM [4–17]. Treatment produces
significant urinary glucose loss with beneficial
effects on glycemic control, body weight, and
blood pressure (BP) [5–17]. Small increases in
low-density lipoprotein cholesterol (LDL-C) and
high-density lipoprotein cholesterol (HDL-C)
have been observed, with the ratio remaining
unchanged [5–17].
Canagliflozin is not associated with
hypoglycemia when used in isolation,
although rates may be increased when used in
conjunction with insulin or insulin
secretagogues [5–17]. The risks of genital
mycotic infections and lower urinary tract
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infections, but not upper urinary tract
infections, are elevated with canagliflozin [18,
19].
This report defines the effects of
canagliflozin on indicators of glycemia, safety,
and tolerability compared to placebo in a subset
of patients who were on background
sulfonylurea monotherapy in a prespecified
substudy of the CANagliflozin cardioVascular
Assessment Study (CANVAS).
METHODS
Overall Design of the CANVAS Trial
CANVAS is a randomized, double-blind,
placebo-controlled, parallel-group, multi-
center trial. A total of 4330 individuals have
been randomized to placebo, canagliflozin
100 mg or canagliflozin 300 mg (Janssen
Pharmaceuticals, Inc.; Titusville, NJ, USA) [20].
Objectives and Specific Hypotheses
for the Sulfonylurea Substudy
The prespecified CANVAS sulfonylurea
substudy was designed to determine the effects
of canagliflozin when used in addition to
sulfonylurea monotherapy on efficacy, safety,
and tolerability in patients with T2DM with
inadequate glycemic control at 18 weeks
without compromising the masked study
design of the entire study cohort. The
objectives of the substudy were to assess the
changes in glycated hemoglobin (HbA1c) and
effects on safety and tolerability with
canagliflozin 100 and 300 mg compared to
placebo at 18 weeks. A greater reduction in
HbA1c with each dose of canagliflozin
compared to placebo was the primary
hypothesis to be tested.
Secondary objectives of the substudy were to
assess the effects of canagliflozin 100 and
300 mg compared to placebo on body weight,
fasting plasma glucose (FPG), proportion of
participants reaching HbA1c \7.0%, systolic
and diastolic BP, fasting plasma lipids (i.e.,
triglycerides, HDL-C, LDL-C, total cholesterol,
and LDL-C to HDL-C ratio) at 18 weeks.
Prespecified hypotheses were evaluated for
effects on body weight, FPG, proportion of
participants reaching HbA1c \7.0%, systolic
BP, triglycerides, and HDL-C.
Recruitment
Patient recruitment methods for CANVAS
(ClinicalTrials.gov Identifier: NCT01032629)
have been previously described [20].
Participant Inclusion and Exclusion
Criteria
Participants in the CANVAS trial are men and
women aged C30 years with T2DM with
inadequate glycemic control (HbA1c C7.0%
and B10.5%) on current antihyperglycemic
therapies and at increased risk of
cardiovascular disease [20]. The specific
inclusion and exclusion criteria and the
overall CANVAS trial design (including
screening and run-in procedures,
randomization, and follow-up procedures)
have been previously published [20].
The subset included in the sulfonylurea
substudy are the participants who were taking
minimum or above specified doses of
sulfonylurea monotherapy at baseline,
specifically glipizide 20 mg, glipizide extended
release 10 mg, glyburide/glibenclamide 10 mg,
glimepiride 4 mg, gliclazide 160 mg, or
gliclazide modified release (MR) 60 mg (i.e., at
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least half the maximum labeled dose of
sulfonylurea).
Background Drug Treatments
Participants were required to have stable
background sulfonylurea monotherapy for
8 weeks prior to screening and to continue on
the same sulphonylurea dose if at all possible
for 18 weeks to allow for the evaluation of
short-term effects of canagliflozin on
biomarkers while participants were on stable
background therapy. Criteria for the initiation
of glycemic rescue therapy have been published
[20]. In summary, glycemic rescue therapy was
either up-titration of current sulfonylurea or the
stepwise addition of non-insulin AHA(s), and
then insulin therapies, instituted by
investigators using local guidelines for
glycemic targets.
Outcomes
The primary efficacy outcome for this substudy
was change in HbA1c from baseline to week 18.
The secondary efficacy outcomes evaluated at
week 18 were body weight, FPG, proportion of
participants reaching HbA1c\7.0%, systolic BP,
triglycerides, and HDL-C.
Adverse events (AEs), including
preidentified AEs of interest (i.e., genital
mycotic infections, urinary tract infections,
and AEs related to osmotic diuresis and
reduced intravascular volume) were recorded.
Hypoglycemia episodes were also reported and
were defined as biochemically documented
(concurrent finger-stick or plasma glucose
B3.9 mmol/L, irrespective of symptoms) and
severe (i.e., requiring the assistance of another
individual or resulting in seizure or loss of
consciousness).
Statistical Analyses
Efficacy and safety analyses were performed using
themodified intent-to-treatpopulation, consisting
of all randomizedpatientswho receivedC1dose of
study drug. The last observation carried forward
approachwasused to imputemissing efficacydata.
An analysis of covariance model including
treatment as a fixed effect and corresponding
baseline value as a covariate was used for primary
and continuous secondary endpoints. Least
squares means and 2-sided 95% confidence
intervals (CIs) were calculated for the comparison
of each canagliflozindose versus placebo.A logistic
regression model with treatment as a factor and
baseline HbA1c as a covariate was used for the
analysis of the proportion of patients reaching
HbA1c\7.0%. A prespecified, hierarchical testing
sequence was used to evaluate the prespecified
18-week hypotheses and estimate P values. For
endpoints that were not prespecified for
hypothesis testing, point estimates and 95% CIs
are provided in lieu of P values. For patients who
received rescue therapy, the lastpost-baselinevalue
prior to the initiationof rescue therapywasused for
analysis. Finally, the efficacy analyses were
repeated for all CANVAS trial participants who
recorded use of any sulfonylurea dose in
monotherapy at baseline (data not shown, but
conclusionsnotdifferent).Data forotheroutcomes
remain blinded. Statistical analyses were
performed using SAS, version 9.2 (Cary, NC, USA).
Compliance with Ethics
The study is being conducted in accordance
with the ethical standards of the responsible
committee on human experimentation
(institutional and national) and with the
Helsinki Declaration of 1964, as revised in
2013, and is consistent with Good Clinical
292 Diabetes Ther (2015) 6:289–302
Practice. Regulatory approval for the conduct of
the trial was obtained in each country, and
ethics approval was received for every site prior
to initiation. Informed consent was obtained
from all patients included in the CANVAS trial.
RESULTS
During a recruitment period of 15 months, 7691
individuals were screened and 4330 were
randomized (Fig. 1). The CANVAS trial
participants who met the inclusion criteria for
this sulfonylurea substudy (sulfonylurea
monotherapy at the prespecified minimum
doses) were 127 individuals, of whom 119
(93.7%) completed the 18-week treatment
period. A further 88 patients at baseline were
receiving sulfonylurea monotherapy at less
than the prespecified doses; when the total
sulfonylurea-taking population was analyzed,
Fig. 1 Study ﬂow diagram. ALT alanine aminotransferase,
CANA canagliﬂozin, CANVAS CANagliﬂozin cardioVas-
cular Assessment Study, eGFR estimated glomerular
ﬁltration rate, LOCF last observation carried forward,
mITT modiﬁed intent-to-treat, PBO placebo, SU
sulfonylurea
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the conclusions were the same as from the
predefined analysis (data not shown). Amongst
the 127 patients in the primary analysis, 45
were assigned to placebo, 42 to canagliflozin
100 mg, and 40 to canagliflozin 300 mg. No
patients in the canagliflozin 300 mg group
required rescue therapy in the first 18 weeks,
while 4.8% (2 patients) of the canagliflozin
100 mg group and 17.8% (8 patients) of the
placebo group did.
Baseline Characteristics of Participants
Baseline demographic and disease characteristics
were generally similar across treatment groups
(Table 1). At entry to the study, mean age was
64.8 years, HbA1c was 8.4%, body mass index was
29.9 kg/m2, and the median duration of diabetes
was 10.2 years. The estimated glomerular
filtration rate (eGFR) was 69.3 mL/min/1.73 m2
and FPG was 10.0 mmol/L. The most common











Male 26 (58) 24 (57) 22 (55) 72 (57)
Female 19 (42) 18 (43) 18 (45) 55 (43)
Mean ± SD age, years 64.8 ± 7.8 64.1 ± 7.5 65.5 ± 7.8 64.8 ± 7.7
Race, n (%)a
White 34 (76) 30 (71) 31 (78) 95 (75)
Black or African American 1 (2) 0 0 1 (1)
Asian 9 (20) 12 (29) 8 (20) 29 (23)
Otherb 1 (2) 0 1 (3) 2 (2)
Mean ± SD body weight, kg 85.2 ± 19.3 83.7 ± 17.4 79.9 ± 19.5 83.0 ± 18.7
Mean ± SD BMI, kg/m2 30.7 ± 6.1 30.2 ± 5.0 28.7 ± 6.2 29.9 ± 5.8
Mean ± SD eGFR, mL/min/1.73 m2 68.8 ± 18.8 71.5 ± 18.4 67.7 ± 18.7 69.3 ± 18.6
Mean ± SD duration of T2DM, years 11.4 ± 6.7 10.6 ± 5.9 8.4 ± 6.2 10.2 ± 6.4
Mean ± SD HbA1c, % 8.5 ± 1.13 8.3 ± 0.82 8.2 ± 1.01 8.4 ± 1.00
Mean ± SD FPG, mmol/L 10.3 ± 2.68 10.1 ± 2.67 9.7 ± 2.28 10.0 ± 2.55
Microvascular complications, n (%) 18 (40) 15 (36) 22 (55) 55 (43)
BMI body mass index, CANA canagliﬂozin, eGFR estimated glomerular ﬁltration rate, FPG fasting plasma glucose, HbA1c
glycated hemoglobin, PBO placebo, SD standard deviation, T2DM type 2 diabetes mellitus
a Percentages may not total 100% due to rounding
b Including other
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sulfonylurea therapies were glimepiride (35%),
glyburide/glibenclamide (29%), and gliclazide MR
(27%).
Effects of Canagliflozin on Efficacy
Outcomes
Both doses of canagliflozin significantly reduced
the primary outcome of HbA1c relative to
placebo at week 18 (placebo-subtracted
changes [95% CI] of -0.74% [-1.15, -0.33;
P\0.001] and -0.83% [-1.24, -0.42;
P\0.001] with canagliflozin 100 and 300 mg,
respectively; Table 2; Fig. 2) and a higher
proportion of patients treated with
canagliflozin 100 and 300 mg achieved HbA1c
\7.0% versus placebo (25.0% and 33.3% vs
5.0%, respectively). FPG was also lower with
both doses (Fig. 3; Table 2). There was also a
statistically significant reduction in the
secondary outcome of body weight with
canagliflozin 300 mg but not canagliflozin
100 mg (Fig. 4; Table 2). There were no notable
differences detected in systolic BP with
canagliflozin 100 or 300 mg (Table 2). Clear
effects on blood lipids were not apparent, with
large CIs about most estimates (Fig. 5).
Effects of Canagliflozin on Safety
and Tolerability Outcomes
AEs were reported for 66.7%, 26.2%, and 45.0%
of participants treated with placebo,
canagliflozin 100 mg, and canagliflozin
300 mg, respectively (Table 3). The
corresponding figures for serious AEs were
8.9%, 0%, and 7.5%, respectively, with no
specific serious AE terms reported in more
than 1 patient in any group. AEs leading to
discontinuation of treatment were numerically
similar with canagliflozin 300 mg compared to
canagliflozin 100 mg and placebo. Genital
mycotic infections were more common with
canagliflozin compared with placebo for
women (5.6% [1/18], 5.6% [1/18], and 0% [0/
19] with canagliflozin 100 and 300 mg and
placebo, respectively), and no genital mycotic
infections were reported in men across groups;
Table 2 Effects of canagliﬂozin on primary and secondary outcomes
Treatment difference, 95% CI
CANA 100 mg vs PBO CANA 300 mg vs PBO
HbA1c, %a –0.74 –1.15 to -0.33 –0.83 –1.24 to –0.42
% change in body weightb –0.4 –1.8 to 1.0 –1.8 –3.2 to –0.4
FPG, mmol/L –2.1 –3.0 to -1.2 –2.7 –3.6 to –1.7
Proportion with HbA1c\7.0%, % 20.0 2.5 to 37.5 28.3 9.5 to 47.1
Systolic BP, mmHg –0.10 –6.45 to 6.25 –1.77 –8.21 to 4.67
% change in HDL-C 2.7 –5.3 to 10.7 0.9 –7.1 to 8.8
% change in triglycerides –13.0 –28.5 to 2.6 12.0 –3.0 to 27.1
% change in LDL-C –1.1 –13.3 to 11.1 3.7 –8.5 to 15.9
BP blood pressure, CANA canagliﬂozin, CI conﬁdence interval, FPG fasting plasma glucose, HbA1c glycated hemoglobin,
PBO placebo, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol
a Both doses vs PBO, P\0.001
b CANA 100 mg vs PBO, P = 0.557; CANA 300 mg vs PBO, P = 0.014
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there was no evidence of an increased rate of
upper or lower urinary tract infection. AEs
attributable to volume depletion, such as
postural hypotension and dizziness, were more
common with active treatment compared to
placebo. The rates of documented
hypoglycemia were greater with canagliflozin
than placebo, and there were no cases defined as
severe hypoglycemia reported across treatment
groups (Table 3). Small to moderate mean
percent changes from baseline in serum
creatinine were observed with canagliflozin
100 and 300 mg and placebo (4.1%, 9.9%, and
5.7%, respectively). The largest increase in
serum creatinine occurred by week 6 in both
the canagliflozin 100 and 300 mg groups, and
the levels were trending toward baseline by
week 18. Similar but reciprocal differences in
Fig. 2 Effects of canagliﬂozin on HbA1c (LOCF). CANA canagliﬂozin, HbA1c glycated hemoglobin, LOCF last
observation carried forward, LS least squares, PBO placebo, SE standard error, wk week
Fig. 3 Effects of canagliﬂozin on FPG (LOCF). CANA
canagliﬂozin, FPG fasting plasma glucose, LOCF last
observation carried forward, LS least squares, PBO placebo,
SE standard error, wk week. Asterisk Not statistically
signiﬁcant vs PBO based on the hypothesis testing sequence
(nominal P\0.001)
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the mean percent change from baseline in eGFR
were observed with canagliflozin 100 and
300 mg and placebo (-2.5%, -9.6%, and
–4.7%, respectively).
DISCUSSION
The addition of canagliflozin to background
sulfonylurea monotherapy was efficacious, with
further placebo-adjusted decreases of HbA1c of
-0.74% and -0.83% for canagliflozin 100 and
300 mg, respectively, at 18 weeks. Furthermore,
the reductions in HbA1c were accompanied by a
significant decrease in body weight for the
300-mg dose (-1.8%) although not for the
100-mg dose. Canagliflozin 100 mg has been
associated with consistent weight loss in other
Phase 3 studies [5–17], with significant weight
loss observed with canagliflozin 100 mg versus
placebo (–1.4%) in the 26-week study as add-on
Fig. 4 Effects of canagliﬂozin on body weight (LOCF). CANA canagliﬂozin, LOCF last observation carried forward, LS
least squares, PBO placebo, SE standard error, wk week. Asterisk Not statistically signiﬁcant vs PBO
Fig. 5 Effects of canagliﬂozin on fasting plasma lipids
(LOCF). CANA canagliﬂozin, HDL-C high-density
lipoprotein cholesterol, LDL-C low-density lipoprotein
cholesterol, LOCF last observation carried forward, LS least
squares, PBO placebo, SE standard error. Asterisk Units of
mol/mol for LDL-C/HDL-C
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to metformin plus sulfonylurea [6]. Thus, it
seems unlikely that the addition of
canagliflozin to the background of a
sulfonylurea alone would diminish the extent
of weight loss and suggests that the modest
reduction in body weight with canagliflozin
100 mg in this study is likely an outlying
estimate. Changes in BP, while not significant,
were in a similar direction to those observed in
other reports [5–17]. Effects on lipid metabolism
were also inconsistent and nonsignificant, but
the overall pattern appeared to be similar to
Table 3 Overall safety and selected adverse events
Patients, n (%)
PBO (n5 45) CANA 100 mg (n5 42) CANA 300 mg (n5 40)
Any AEs 30 (66.7) 11 (26.2) 18 (45.0)
AEs causing discontinuation 0 1 (2.4) 1 (2.5)
AEs related to study druga 8 (17.8) 3 (7.1) 6 (15.0)
Serious AEs 4 (8.9)b 0 3 (7.5)c
Deaths 0 0 0
AEs of special interest
Genital mycotic infections
Male 0 0 0
Femaled,e 0 1 (5.6) 1 (5.6)
Urinary tract infections 1 (2.2) 1 (2.4) 1 (2.5)
Osmotic diuresis-related events
Pollakiuria 0 1 (2.4) 2 (5.0)
Polyuria 1 (2.2) 1 (2.4) 0
Volume-related events
Postural dizziness 0 0 0
Orthostatic hypotension 0 0 0
Documented hypoglycemiaf,g 2 (4.4) 0 6 (15.0)
Severe hypoglycemia 0 0 0
AE adverse event, CANA canagliﬂozin, PBO placebo
a Possibly, probably, or very likely related to study drug, as assessed by investigators
b Including asthma, atrioventricular block second degree, blood creatinine increased, diabetes mellitus, ﬂank pain, and
hyperglycemia
c Including angina pectoris, ankle fracture, colon cancer metastatic, and coronary artery disease
d The proportions of female genital mycotic infections were calculated using the number of female patients in each
treatment group, as follows: PBO, n = 19; CANA 100 mg, n = 18; CANA 300 mg, n = 18
e Including vaginal infection and vulvovaginitis
f All documented hypoglycemia episodes are reported for prior to rescue therapy
g Documented hypoglycemia included episodes that were biochemically documented (B3.9 mmol/L) or severe (i.e.,
requiring the assistance of another individual or resulting in seizure or loss of consciousness)
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that reported previously in larger, better
powered studies with small increases in LDL-C
[5–17]. Importantly, there was no change in the
LDL-C/HDL-C ratio with either canagliflozin
300 or 100 mg.
The observed additive glycemic effects of
canagliflozin on top of sulfonylurea are
anticipated on the basis of its complementary
mechanism of action, and while the efficacy of
sulfonylurea is dependent on adequate
pancreatic insulin-secretory capacity, this is
not the case with the SGLT2 inhibitors. For
this reason, it is hypothesized that canagliflozin
will be an effective treatment choice at most
stages of the disease, and in combination with
other glucose-lowering therapies. The 300-mg
dose of canagliflozin was associated with
numerically greater effects on several
parameters compared with the 100-mg dose,
including a modest increase in the percentage
of patients achieving a target HbA1c \7.0%
(placebo-subtracted differences of 28.3% vs
20.0%, respectively).
We and others have previously reported that
the additional efficacy effects of the 300-mg
over the 100-mg dose were achieved at the
expense of an increased risk of drug-related AEs
[5–17]. By contrast, (almost certainly as the
result of the much smaller study numbers),
osmotic diuresis-related (e.g., polyuria,
pollakiuria, thirst) and volume-related AEs
(e.g., postural dizziness, orthostatic
hypotension, hypotension, syncope,
presyncope) were similar in all treatment
groups, with no difference between the 2
canagliflozin doses. We should not, however,
conclude that the combination of canagliflozin
with a sulfonylurea provides a protective effect
against these side effects, and identifying
patients potentially susceptible to AEs will be
an important component of a patient-centered
approach to diabetes management. At the same
time, it reinforces the impression that serious
adverse effects are relatively uncommon with
this compound.
The other AEs observed with canagliflozin
were those generally recognized for SGLT2
inhibitors [21]. Genital mycotic infections
were more common with canagliflozin than
placebo. As has been reported, they were
generally mild or moderate in intensity, were
managed with usual therapies, and treatment
was continued [19]. There was no evidence of
an increased rate of either upper or lower
urinary tract infections, although this is a
recognized potential complication with this
drug class in larger datasets [21]. The observed
decline in eGFR is likely to be hemodynamic in
origin and was not associated with an excess of
renal AEs. The small size of the decline in eGFR
and the other favorable metabolic effects
suggest that the net impact of canagliflozin on
renal outcomes is unlikely to be harmful.
The primary weakness of this study is the
relatively small sample size. This almost
certainly reflects a decrease in the use of
sulfonylureas as initial therapy in general, and
the small proportion of diabetic patients
managed on sulfonylurea monotherapy. As
such, the confidence intervals about many
estimates are wide, and, while the point
estimates of effects sometimes appear different
to those reported in prior studies, it is difficult
to know whether this reflects real differences in
efficacy and safety or chance. In this context,
these substudy findings are best interpreted in
the context of the broader experience with
canagliflozin in this and other patient groups.
The conduct of the analyses at 18 weeks
provides estimates of short-term effects only,
with the long-term impact of canagliflozin in
this group remaining to be established.
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CONCLUSION
Canagliflozin appears to offer significant and
clinically meaningful benefits when used in
conjunction with sulfonylureas with a similar
class-effect AE profile. Overall, findings from
this study support the efficacy and safety of
canagliflozin as add-on to sulfonylurea
monotherapy in patients with T2DM and
cardiovascular risk.
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